SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Upgraded by Zacks Research

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on the stock. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. HC Wainwright lifted their price target on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday. Chardan Capital lifted their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Finally, Rodman & Renshaw reissued a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

SAB Biotherapeutics Trading Down 2.7%

Shares of NASDAQ SABS opened at $3.62 on Monday. The company’s fifty day moving average is $3.86 and its 200-day moving average is $3.81. The stock has a market cap of $184.44 million, a price-to-earnings ratio of -1.56 and a beta of 0.55. SAB Biotherapeutics has a twelve month low of $1.60 and a twelve month high of $6.60. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Equities research analysts predict that SAB Biotherapeutics will post -1.1 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Commodore Capital LP acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth $8,847,000. HB Wealth Management LLC acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth $618,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth $40,000. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $34,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth $32,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.